Tirz 30 features Tirzepatide, a cutting-edge dual-agonist peptide that targets both GIP and GLP-1 receptors. Preclinical studies suggest this dual mechanism offers enhanced metabolic effects over traditional single-agonist treatments, including reduced appetite, improved insulin sensitivity, and accelerated fat metabolism. This research-grade compound is supplied in lyophilized form to ensure long-term preservation and bioactivity.